Women with vaginal fungal infections suffer more severely than migraine patients. Out of shame, they often keep quiet and even try to treat themselves - sometimes with fatal consequences. At MedUni Vienna and MedUni Innsbruck, together with over 20 other European study centers, final tests are now being carried out on a promising cream that could provide a complete cure for vaginal mycosis. For these final studies prior to market approval, test subjects are being sought who are frequently affected by vaginal mycosis.
Montavit researches cure for vaginal fungus with ProFem
The Tyrolean pharmaceutical company Montavit and the Viennese biotech startup ProFem have entered into a strategic partnership to develop a new drug. This is intended to bring about a fundamental change in the medical care of vaginal mycosis patients Since this disease affects a great many women worldwide, this project may represent a breakthrough in the treatment of infectious diseases.
ProFem tests cream for the treatment of vaginal mycosis in Vienna and Tyrol: test subjects wanted
75 percent of all women suffer from a painful vaginal fungal infection at least once in their lives. A promising cream is now being tested at MedUni Vienna and Innsbruck University Hospital that could provide a complete cure for the infectious disease. Test subjects with acute or chronic vaginal mycosis are being sought for the study.
Chronic vaginal mycosis: test phase for promising therapeutic from Austria
New opportunities for the treatment of acute as well as chronic vaginal fungal diseases. The Viennese biotech company ProFem recently announced the start of the Phase 2a study (proof of concept) of the innovative therapeutic Candiplus. The goal is to completely cure fungal infections in women. Initial study results are expected at the end of 2017.
